Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.

Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.

The company secures funding to push its lead candidate towards US approval.

Prexasertib data worsen again, and biomarkers are up in the air.

Readout of the Pivot-006 trial is brought forward by nearly a year.

$650m buys the group rights to RemeGen’s RC148.